WO2021172900A1 - 락토바실러스 헬베티쿠스 균주 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 - Google Patents
락토바실러스 헬베티쿠스 균주 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2021172900A1 WO2021172900A1 PCT/KR2021/002389 KR2021002389W WO2021172900A1 WO 2021172900 A1 WO2021172900 A1 WO 2021172900A1 KR 2021002389 W KR2021002389 W KR 2021002389W WO 2021172900 A1 WO2021172900 A1 WO 2021172900A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- lactobacillus helveticus
- strain
- inflammatory
- kctc
- Prior art date
Links
- 240000002605 Lactobacillus helveticus Species 0.000 title claims abstract description 64
- 235000013967 Lactobacillus helveticus Nutrition 0.000 title claims abstract description 52
- 229940054346 lactobacillus helveticus Drugs 0.000 title claims abstract description 52
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 44
- 230000000968 intestinal effect Effects 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000002577 cryoprotective agent Substances 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000004232 Enteritis Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 206010038910 Retinitis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 201000004537 pyelitis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000004580 weight loss Effects 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 238000002483 medication Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 26
- 235000009200 high fat diet Nutrition 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 13
- 239000004310 lactic acid Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 244000057717 Streptococcus lactis Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229920003045 dextran sodium sulfate Polymers 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 208000009137 Behcet syndrome Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010074063 Ischaemic enteritis Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- -1 and the like Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present invention relates to a Lactobacillus helveticus strain and a composition for preventing or treating an inflammatory disease comprising the same.
- Inflammatory Bowel Disease inflammatory bowel disease
- Inflammatory Bowel Disease is a disease in which abnormal chronic inflammation in the intestinal tract repeats improvement and recurrence. etc.
- the clear pathogenesis of inflammatory bowel disease has not yet been elucidated, and it is known that genetic and immunological abnormalities and environmental factors such as stress or drugs are related.
- sulfasalazine is used as a treatment for inflammatory bowel disease, it has side effects such as nausea, vomiting, loss of appetite, headache, and anemia. Therefore, there is a continuous need for research and development for a therapeutic agent for inflammatory bowel disease that has no side effects and is safe.
- probiotics for preventing or treating inflammatory bowel disease using fungi that have been considered safe microorganisms are being actively studied.
- lactic acid bacteria related to the prevention and treatment effect of inflammatory bowel disease
- Lactobacillus It has been reported that casei suppresses the expression of inflammatory cytokines IL-12 or TNF- ⁇ (Matsumoto, S., et al. Clin Exp Immunol . 2005, 140, 417-426).
- Bifidobacterium. bifidum L. casei , L. acidophilus , L. reuteri and Streptococcus.
- the present inventors studied to develop a new strain with excellent effects on inflammatory bowel disease.
- the Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) showed an excellent therapeutic effect on inflammatory bowel disease.
- the invention was completed.
- Lactobacillus helveticus ( Lactobacillus helveticus ) It provides a strain (Accession No.: KCTC 14110BP).
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating an inflammatory disease comprising a Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof as an active ingredient.
- a Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof as an active ingredient.
- Another aspect of the present invention provides a food composition for preventing or inhibiting an inflammatory disease comprising a Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof.
- a Lactobacillus helveticus strain accesion No.: KCTC 14110BP
- KCTC 14110BP Lactobacillus helveticus strain
- Another aspect of the present invention provides a feed composition for preventing or inhibiting an inflammatory disease comprising a Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof.
- a Lactobacillus helveticus strain accesion No.: KCTC 14110BP
- KCTC 14110BP Lactobacillus helveticus strain
- Lactobacillus Helveticus ( Lactobacillus Helveticus ) It provides a method of preventing and treating an inflammatory disease comprising administering to a subject a strain (Accession No.: KCTC 14110BP) or a culture thereof.
- the Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) of the present invention relieves symptoms such as weight loss and intestinal length decrease in inflammatory bowel disease, and there is no side effect seen in conventional drug treatments. Therefore, the Lactobacillus helveticus strain can be usefully used for treating inflammatory diseases, particularly inflammatory bowel disease.
- HFD inflammatory bowel disease-induced mice
- NCD inflammatory bowel disease-induced mice
- Figure 2 is a diagram showing the degree of tissue damage (Figure 2a) and the degree of impairment (Figure 2b) of inflammatory bowel disease-inducing mice (HFD) ingested in a high-fat diet and inflammatory bowel disease-inducing mice (NCD) ingested in a general diet. (**p ⁇ 0.01; ***p ⁇ 0.001, NCD vs HFD).
- Figure 3 is a photograph of staining the intestinal tissue of inflammatory bowel disease-induced mice (HFD) ingested in a high-fat diet and inflammatory bowel disease-induced mice (NCD) ingested in a general diet.
- HFD inflammatory bowel disease-induced mice
- NCD inflammatory bowel disease-induced mice
- FIG. 4 is a view showing an experimental schedule for screening strains having a therapeutic effect on inflammatory bowel disease in an embodiment of the present invention.
- 5 and 6 are diagrams showing changes in body weight after oral administration of 10 types of lactic acid bacteria to inflammatory bowel disease-induced mice ingested in a high-fat diet (*p ⁇ 0.05, L.helveticus vs Mock).
- FIG. 7 and 8 are diagrams showing the survival rate for 20 days after each oral administration of 10 types of lactic acid bacteria to inflammatory bowel disease-induced mice ingested in a high-fat diet.
- FIG. 9 is a view showing the intestinal length of mice orally administered L. helveticus MG585 strain or L. lactis strain to inflammatory bowel disease-induced mice ingested in a high-fat diet (*p ⁇ 0.05, L.helveticus vs Mock).
- Figure 10 is a photograph of measuring the intestinal length of mice orally administered L. helveticus MG585 strain or L. lactis strain to inflammatory bowel disease-induced mice ingested in a high-fat diet.
- 11 is a photograph of staining of intestinal tissues of mice orally administered with L. helveticus MG585 strain or L. lactis strain to inflammatory bowel disease-induced mice ingested in a high-fat diet.
- Lactobacillus helveticus Lactobacillus helveticus It provides a strain (Accession Number: KCTC 14110BP).
- the Lactobacillus ( Lactobacillus ) is an aerobic or facultative anaerobic Gram-positive bacillus genus microorganism widely distributed in nature. Microorganisms belonging to the genus Lactobacillus include Lactobacillus helveticus and Sakei.
- the present inventors selected a novel Lactobacillus helveticus strain having a therapeutic effect on excellent inflammatory diseases, particularly inflammatory bowel disease, and named it "Lactobacillus helveticus MG585".
- the strain was deposited as an international patent under the accession number KCTC 14110BP on January 14, 2020 at the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center. In addition, the strain corresponds to a probiotic strain, is harmless to the human body, and can be used without side effects.
- L. helveticus MG585 used in the present invention may be described in combination as L. helveticus MG585 or Lactobacillus helveticus strain (Accession No.: KCTC 14110BP).
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating an inflammatory disease comprising a Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof as an active ingredient.
- a Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof as an active ingredient.
- the Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) is the same as described above.
- the strain may be a live cell or a dead cell, preferably a live cell.
- the culture of the strain may or may not contain the strain, and preferably may be included.
- the culture of the strain may be in the form of a lysate.
- the active ingredient Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof is included in a therapeutically effective amount or nutritionally effective concentration, preferably 10 8 to 10 12 CFU It contains a content of /g, or includes a culture with an equal number of live cells.
- a therapeutically effective amount or nutritionally effective concentration preferably 10 8 to 10 12 CFU It contains a content of /g, or includes a culture with an equal number of live cells.
- 1 ⁇ 10 6 or more live cells preferably 1 ⁇ 10 8 to 1 ⁇ 10 12 CFU/g of live cells, may be administered once or dividedly over several times.
- the Lactobacillus helveticus strain may have a therapeutic effect on inflammatory bowel disease.
- the weight of the mice increased.
- weight loss occurred in mice orally administered with 9 different lactic acid bacteria ( FIGS. 5 and 6 ).
- the Lactobacillus helveticus strain accesion No.: KCTC 14110BP was orally administered, not a single mouse died.
- inflammation is a response to protect the living body against harmful factors, and immune cells, blood vessels and inflammatory mediators are involved to inhibit cell damage, remove damaged tissue and necrotic cells, and It involves a series of processes of regeneration.
- Inflammatory disease is a generic term for diseases in which inflammation is the main lesion.
- the inflammatory disease is inflammatory bowel disease, systemic lupus erythematosus, scleroderma, atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis , osteoporosis, allergy, diabetes, diabetic nephropathy, pyelitis, nephritis, Sjogren's syndrome, autoimmune pancreatitis, periodontal disease, asthma, graft-versus-host disease, chronic pelvic inflammatory disease, endometritis, rhinitis, transplant rejection and chronic prostatitis It may be any one selected from the group.
- the inflammatory bowel disease may be any one disease selected from the group consisting of Crohn's disease, ulcerative colitis, intestinal Bechet's disease, and enteritis.
- inflammatory bowel disease is a disease that causes chronic inflammation in the gastrointestinal tract, and is a disease that occurs in all intestines, such as bacterial, viral, amoebic, tuberculous enteritis, ischemic enteritis, and radiation enteritis. It may include any inflammatory disease. Although the cause of inflammatory bowel disease has not been clearly identified, it is known that it is influenced by genetic and environmental factors and is mediated by immunological abnormalities.
- Crohn's disease is a chronic inflammatory bowel disease that appears throughout the gastrointestinal tract from the oral cavity to the anus. As an autoimmune disease, most of it occurs in the ileocecal region, which is the boundary between the small intestine and the large intestine, and occurs frequently in the large intestine, the distal end of the ileum, and the small intestine. Crohn's disease is characterized by repeating symptomatic and asymptomatic periods with symptoms such as abdominal pain and diarrhea. The cause of the disease is not clear, but it is presumed that mycobacterial infection, measles virus infection, and an excessive immune response to normal bacteria in the digestive tract are involved.
- ulcerative colitis is a type of diffuse nonspecific inflammation disease that mainly invades the mucous membrane, and forms a rash or ulcer.
- the cause of ulcerative colitis is not clearly known, and it causes various systemic symptoms such as bloody diarrhea.
- Behçet's disease is a disease in which oral and genital ulcers and eye inflammation appear repeatedly, and is a systemic and chronic disease that affects the cardiovascular system, nervous system, digestive tract, liver, spleen, kidney and lungs. When Behcet's disease invades the intestinal tract, it is called “long-form Behcet's disease.” Enteric Behcet's disease is a non-specific and recurrent chronic inflammatory disease that is accompanied by symptoms such as abdominal pain and diarrhea, and is also accompanied by complications such as bleeding and perforation.
- prevention refers to any action that inhibits or delays the occurrence, spread, and recurrence of a target disease by administration of the composition.
- treatment refers to any action in which the symptoms of the target disease are improved or beneficially changed by the administration of the composition. Specifically, it includes curing, alleviating, preventing, preventing, delaying or reducing symptoms caused by an inflammatory disease.
- composition of the present invention may be formulated in a suitable form together with at least one or more pharmaceutically acceptable carriers, and may further contain a cryoprotectant, excipient or diluent.
- cryoprotectant means that it is physiologically acceptable and does not normally cause severe gastrointestinal disturbances, dizziness, allergic reactions or similar reactions when administered to humans.
- cryoprotectant may be at least one selected from the group consisting of glycerol, trehalose, maltodextrin, powdered skim milk and starch.
- excipient may be one or more selected from the group consisting of glucose, dextrin, and powdered skim milk.
- the cryoprotectant may be included in 0.01 wt% to 20 wt%, 0.01 wt% to 10 wt%, based on the total weight of the composition, specifically, the glycerol is 5 wt% to 20 wt%, and the trehalose is 2 wt% to 10 wt% Weight%, the maltodextrin may be included in an amount of 2 wt% to 10 wt%, the skim milk powder in an amount of 0.5 wt% to 2 wt%, and the starch content in an amount of 0.1 wt% to 1 wt%.
- the excipient may be included in an amount of 75 wt% to 95 wt% or 85 wt% to 95 wt% based on the total weight of the composition.
- Carriers and diluents that may be included in the pharmaceutical composition include gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydro oxybenzoate, talc, magnesium stearate and mineral oil.
- it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- a pharmaceutically acceptable carrier it may further include a carrier for oral administration.
- Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
- Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite or ascorbic acid.
- Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
- the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, etc. in addition to the above components.
- composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally.
- the pharmaceutical composition of the present invention may be formulated as a formulation for oral administration according to the route of administration as described above.
- the composition of the present invention may be formulated as a powder, granule, tablet, pill, dragee, capsule, liquid, gel, syrup, slurry, suspension, etc. using methods known in the art.
- oral preparations can be obtained by blending the active ingredient with a solid excipient, pulverizing it, adding a suitable adjuvant, and processing it into a granule mixture to obtain tablets or dragees.
- excipients include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches, including corn starch, wheat starch, rice starch and potato starch, cellulose, Cellulose, including methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose, and the like, fillers such as gelatin, polyvinylpyrrolidone, and the like may be included.
- cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant if necessary.
- the pharmaceutical composition of the present invention may further include an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, and a preservative.
- the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat or prevent a disease at a reasonable benefit/risk ratio applicable to medical treatment or prevention.
- the effective dose level depends on the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion, the duration of treatment, and the present invention used. It can be determined according to factors including drugs used in combination with or concurrently with the composition of the drug and other factors well known in the medical field.
- the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount capable of obtaining the maximum effect with a minimum amount without side effects.
- the pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as the effect of the present invention is exhibited.
- Lactobacillus helveticus ( Lactobacillus helveticus ) It provides a food composition for preventing or inhibiting an inflammatory disease comprising a strain (Accession No.: KCTC 14110BP) or a culture thereof.
- Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) is the same as described above.
- the food composition includes all forms of functional food, nutritional supplement, health food and food additives, etc. Food compositions of this type are known in the art. It can be prepared in various forms according to a conventional method.
- the strain When the strain is used as a food additive, the strain may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In general, it may be added in an amount of 0.0001% by weight to 1% by weight, specifically 0.001% by weight to 0.1% by weight of the raw material composition containing the strain when preparing food or beverage. However, in the case of long-term intake for health and hygiene purposes or for health control purposes, the above amount may be used below the above range.
- Lactobacillus helveticus ( Lactobacillus helveticus ) It provides a feed composition for preventing or inhibiting an inflammatory disease comprising a strain (Accession No.: KCTC 14110BP) or a culture thereof.
- Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) is the same as described above.
- the feed composition for the prevention or improvement of the inflammatory disease can be prepared by adding the Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) in an appropriate effective concentration range according to various feed preparation methods known in the art.
- Another aspect of the present invention provides a method for preventing and treating an inflammatory disease, comprising administering a Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof to an individual.
- a Lactobacillus helveticus strain accesion No.: KCTC 14110BP
- KCTC 14110BP Lactobacillus helveticus strain
- the subject may be an individual having an inflammatory disease.
- the subject may be a mammal, preferably a human.
- the Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) is the same as described above.
- the route of administration of the strain or its culture, the dosage and the number of times of administration, and the type of inflammatory disease are as described above.
- Another aspect of the present invention provides the use of Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) or a culture thereof for the treatment of inflammatory diseases.
- Lactobacillus helveticus strain (Accession No.: KCTC 14110BP) is the same as described above.
- the types of inflammatory diseases are as described above.
- mice were fed a 60% high fat diet (HFD) for 10 weeks, and then 2% (w/v) dextran sodium sulfate (DSS, MP bio, USA) was added to drinking water for 6 days. After mixing with the mixture, they were allowed to ingest water for 2 days, and this was set as the experimental group. Mice fed with a normal diet (Normal Chow Diet, NCD) instead of a high-fat diet were set as a control group.
- HFD high fat diet
- DSS dextran sodium sulfate
- mice in the control group and the experimental group intestinal tissues were extracted and fixed with 10% buffered formalin (Neutral buffered Formalin). After that, paraffin sections were made, stained with Hematoxylin & Eosin (H&E), and histological analysis was performed. Histological analysis was evaluated by dividing it into 1 to 5 points according to the degree of tissue damage and the degree of disability in addition to microscopic observation. The higher the degree of damage or disability, the higher the score.
- Example 2 Screening strains having a therapeutic effect on inflammatory bowel disease and confirming the therapeutic effect
- lactic acid bacteria having a therapeutic effect on inflammatory bowel disease among 10 types of lactic acid bacteria purchased from Mediogen were selected.
- mice C57BL/6 mice were fed a 60% High Fat Diet (HFD) for 12 weeks, and then 2% (w/v) dextran sodium sulfate (DSS, MP bio, USA) for 1 week from the 10th week. ) was mixed with drinking water and allowed to ingest freely. Thereafter, 3% (w/v) sodium dextran sulfate was mixed with drinking water for about 10 days from the 11th week and allowed to be freely ingested.
- Mice fed only a 60% high-fat diet were set as a control group (Mock). Each lactic acid bacteria was orally administered at intervals of 2 to 3 days at 5 ⁇ 10 9 CFU per mouse for 12 weeks. Then, in order to check whether the weight loss symptom, which is one of the representative symptoms of inflammatory bowel disease, is improved, the amount of weight change in the control group and the experimental group was measured ( FIG. 4 ).
- mice orally administered Lactobacillus helveticus MG585 strain body weight increased compared to the control group.
- the mice of the experimental group to which the remaining 9 types of lactic acid bacteria were orally administered except for the Lactobacillus helveticus MG585 strain the body weight was reduced compared to the control group ( FIGS. 5 and 6 ).
- Example 2.1 the survival rates of control (Mock) and experimental group mice were compared during oral administration of sodium dextran sulfate and each lactic acid bacteria from the 10th week onwards.
- the experimental group mice orally administered the L. helveticus MG585 strain which is the most effective in Examples 2.1 and 2.2, and the least effective
- the intestines were removed from the mice of the experimental group to which L. lactis strains were orally administered, and the length of the intestines was measured. At this time, the intestines were also extracted from the mice of the control group (Mock) and the lengths of the intestines were compared.
- Example 2.3 The intestinal tissue extracted in Example 2.3 was fixed with 10% buffered formalin (Neutral buffered Formalin). After that, paraffin sections were made, stained with Hematoxylin & Eosin (H&E), and histological analysis was performed.
- 10% buffered formalin Neuronalin
- H&E Hematoxylin & Eosin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
- 락토바실러스 헬베티쿠스(Lactobacillus Helveticus) 균주(기탁번호: KCTC 14110BP).
- 락토바실러스 헬베티쿠스 균주(기탁번호: KCTC 14110BP) 또는 이의 배양물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물.
- 제2항에 있어서,상기 염증성 질환은 염증성 장질환, 전신성 홍반성 루푸스, 경피증, 아토피성 피부염, 건선, 아나필랙시스, 피부염, 당뇨병성 망막증, 망막염, 황반 변성, 포도막염, 결막염, 관절염, 류마티스성 관절염, 강직성 척추염, 골관절염, 골다공증, 알레르기, 당뇨, 당뇨성 신장병, 신우염, 신장염, 쇼그렌 증후군, 자가 면역 췌장염, 치주질환, 천식, 이식편 대 숙주 질환, 만성 골반 염증 질환, 자궁내막염, 비염, 이식 거부 및 만성 전립선염로 구성되는 군으로부터 선택되는 어느 하나인 것인, 염증성 질환의 예방 또는 치료용 약학 조성물.
- 제3항에 있어서,상기 염증성 장질환은 크론병(Crohn's disease), 궤양성 대장염(ulcerative colitis), 장형 베체트병(intestinal Bechet's disease) 및 장염으로 이루어진 군으로부터 선택되는 어느 하나의 질환인 것인, 염증성 질환 예방 또는 치료용 약학 조성물.
- 제2항에 있어서,상기 조성물은 동결보호제 또는 부형제를 추가로 포함하는, 염증성 질환 예방 또는 치료용 약학 조성물.
- 제5항에 있어서,상기 동결보호제는, 글리세롤, 트레할로스, 말토덱스트린, 탈지분유 및 전분으로 이루어진 군으로부터 선택되는 하나 이상인 것인, 염증성 질환 예방 또는 치료용 약학 조성물.
- 제5항에 있어서,상기 부형제는 포도당, 덱스트린 및 탈지분유로 이루어진 군으로부터 선택되는 하나 이상인 것인, 염증성 질환 예방 또는 치료용 약학 조성물.
- 락토바실러스 헬베티쿠스(Lactobacillus Helveticus) 균주(기탁번호: KCTC 14110BP) 또는 이의 배양물을 포함하는 염증성 질환의 예방 또는 억제용 식품 조성물.
- 락토바실러스 헬베티쿠스(Lactobacillus Helveticus) 균주(기탁번호: KCTC 14110BP) 또는 이의 배양물을 포함하는 염증성 질환의 예방 또는 억제용 사료 조성물.
- 락토바실러스 헬베티쿠스(Lactobacillus Helveticus) 균주(기탁번호: KCTC 14110BP) 또는 이의 배양물을 개체에 투여하는 단계를 포함하는 염증성 질환의 예방 및 치료하는 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180017334.8A CN115551990A (zh) | 2020-02-26 | 2021-02-25 | 瑞士乳杆菌菌株及含有其的用于预防或治疗炎性疾病的组合物 |
EP21761000.5A EP4112716A4 (en) | 2020-02-26 | 2021-02-25 | LACTOBACILLUS HELVETICUS STRAIN AND COMPOSITION CONTAINING IT FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES |
JP2022545847A JP2023516268A (ja) | 2020-02-26 | 2021-02-25 | ラクトバチルス・ヘルベティカス株及びそれを含む炎症性疾患を予防又は処置するための組成物 |
US17/904,939 US20230158087A1 (en) | 2020-02-26 | 2021-02-25 | Lactobacillus helveticus strain and composition containing same for prevention or treatment of inflammatory diseases |
AU2021229110A AU2021229110B2 (en) | 2020-02-26 | 2021-02-25 | Lactobacillus Helveticus strain and composition containing same for prevention or treatment of inflammatory diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0023297 | 2020-02-26 | ||
KR20200023297 | 2020-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021172900A1 true WO2021172900A1 (ko) | 2021-09-02 |
Family
ID=77491766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/002389 WO2021172900A1 (ko) | 2020-02-26 | 2021-02-25 | 락토바실러스 헬베티쿠스 균주 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230158087A1 (ko) |
EP (1) | EP4112716A4 (ko) |
JP (1) | JP2023516268A (ko) |
KR (2) | KR102544149B1 (ko) |
CN (1) | CN115551990A (ko) |
AU (1) | AU2021229110B2 (ko) |
WO (1) | WO2021172900A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115505551A (zh) * | 2022-11-23 | 2022-12-23 | 善恩康生物科技(苏州)有限公司 | 瑞士乳杆菌及其在预防或治疗肾炎中的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116426426B (zh) * | 2023-04-10 | 2024-04-26 | 广东南芯医疗科技有限公司 | 瑞士乳杆菌lh05及其在制备预防或治疗肠道炎症药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004250338A (ja) * | 2003-02-18 | 2004-09-09 | Sunstar Inc | 有用生菌製剤 |
KR102038695B1 (ko) * | 2018-10-30 | 2019-10-30 | 주식회사 종근당바이오 | 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045474A1 (en) * | 2004-10-22 | 2006-05-04 | Medinova Ag | Lactic acid bacteria strains useful against gastrointestinal pathogens and compositions containing same |
GB0903016D0 (en) * | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
KR101087973B1 (ko) * | 2009-06-30 | 2011-12-01 | 일동제약주식회사 | 신규한 락토바실루스 헬베티쿠스, 이의 배양 방법 및 용도 |
US9579353B2 (en) * | 2011-06-10 | 2017-02-28 | Prothera, Inc. | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
KR101355440B1 (ko) * | 2011-10-26 | 2014-02-05 | 주식회사한국야쿠르트 | 류마티스 관절염 예방 효능을 갖는 락토바실러스 헬베티쿠스 에이취와이7801 및 이를 유효성분으로 함유하는 제품 |
US20150202238A1 (en) * | 2012-07-09 | 2015-07-23 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
JP6821643B2 (ja) * | 2013-09-26 | 2021-01-27 | 雪印メグミルク株式会社 | 免疫疾患予防剤 |
CN104187710A (zh) * | 2014-07-28 | 2014-12-10 | 胡安然 | 炎性肠病全营养配方食品 |
CN112195128B (zh) * | 2014-08-29 | 2023-05-02 | 科.汉森有限公司 | 益生菌青春双歧杆菌菌株 |
CN105327338B (zh) * | 2015-11-23 | 2018-11-23 | 东北农业大学 | 一种治疗溃疡性结肠炎的药物及其制备方法 |
IT201600127498A1 (it) * | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
KR102069807B1 (ko) * | 2017-03-09 | 2020-01-28 | 가톨릭대학교 산학협력단 | 유산균 혼합물을 포함하는 면역 질환의 예방 및 치료용 조성물 |
WO2019216662A1 (ko) * | 2018-05-09 | 2019-11-14 | 주식회사 고바이오랩 | 락토바실러스 파라카제이 균주 및 그 용도 |
CN112469812B (zh) * | 2018-05-23 | 2024-01-12 | Ko生物技术有限公司 | 格氏乳杆菌kbl697菌株及其用途 |
WO2021137603A1 (ko) * | 2019-12-31 | 2021-07-08 | 주식회사 지아이바이옴 | 락토바실러스 플란타럼 균주 및 이를 포함하는 대사질환의 예방 또는 치료용 조성물 |
AU2020417121B2 (en) * | 2019-12-31 | 2024-05-02 | Gi Biome | Lactobacillus fermentum strain, and composition for preventing or treating metabolic diseases containing same |
CA3164464A1 (en) * | 2019-12-31 | 2021-07-08 | Gi Biome | Lactobacillus fermentum strain, and composition for preventing or treating metabolic diseases, comprising same |
CN114381398B (zh) * | 2022-01-08 | 2022-06-14 | 浙江大学 | 具有改善酒精性肝病的瑞士乳杆菌zjuids12及其应用 |
CN116064286B (zh) * | 2022-08-19 | 2023-08-11 | 浙江大学 | 具有改善非酒精性肝病的瑞士乳杆菌zjuids11及其应用 |
-
2021
- 2021-02-25 US US17/904,939 patent/US20230158087A1/en active Pending
- 2021-02-25 CN CN202180017334.8A patent/CN115551990A/zh active Pending
- 2021-02-25 EP EP21761000.5A patent/EP4112716A4/en active Pending
- 2021-02-25 WO PCT/KR2021/002389 patent/WO2021172900A1/ko unknown
- 2021-02-25 AU AU2021229110A patent/AU2021229110B2/en active Active
- 2021-02-25 JP JP2022545847A patent/JP2023516268A/ja active Pending
- 2021-02-25 KR KR1020210025410A patent/KR102544149B1/ko active IP Right Grant
-
2023
- 2023-06-09 KR KR1020230074307A patent/KR20230088326A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004250338A (ja) * | 2003-02-18 | 2004-09-09 | Sunstar Inc | 有用生菌製剤 |
KR102038695B1 (ko) * | 2018-10-30 | 2019-10-30 | 주식회사 종근당바이오 | 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물 |
Non-Patent Citations (4)
Title |
---|
KANGIM, JNUTR SCI VITAMINOL., vol. 61, 2015, pages S103 - S105 |
MATSUMOTO, S ET AL., CLIN EXP IMMUNOL., vol. 140, 2005, pages 417 - 426 |
RONG JINGJING, ZHENG HOUFENG, LIU MING, HU XU, WANG TAO, ZHANG XINGWEI, JIN FENG, WANG LI: "Probiotic and anti-inflammatory attributes of an isolate Lactobacillus helveticus NS8 from Mongolian fermented koumiss", BMC MICROBIOLOGY, vol. 15, no. 1, 1 December 2015 (2015-12-01), XP055841052, DOI: 10.1186/s12866-015-0525-2 * |
See also references of EP4112716A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115505551A (zh) * | 2022-11-23 | 2022-12-23 | 善恩康生物科技(苏州)有限公司 | 瑞士乳杆菌及其在预防或治疗肾炎中的应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2021229110A1 (en) | 2022-10-20 |
KR20210108900A (ko) | 2021-09-03 |
KR102544149B1 (ko) | 2023-06-16 |
JP2023516268A (ja) | 2023-04-19 |
EP4112716A4 (en) | 2023-08-16 |
US20230158087A1 (en) | 2023-05-25 |
KR20230088326A (ko) | 2023-06-19 |
TW202140774A (zh) | 2021-11-01 |
CN115551990A (zh) | 2022-12-30 |
AU2021229110B2 (en) | 2024-05-23 |
EP4112716A1 (en) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021172900A1 (ko) | 락토바실러스 헬베티쿠스 균주 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
WO2021137602A1 (ko) | 락토바실러스 퍼멘텀 균주 및 이를 포함하는 대사질환의 예방 또는 치료용 조성물 | |
EP2415475B1 (en) | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum | |
CN108721337B (zh) | 一种预防肿瘤化疗肠道毒性的微生物菌剂 | |
WO2019227418A1 (zh) | 一种组合物及其应用 | |
TW202034776A (zh) | 長雙歧桿菌長亞種、含其的組合物及用途 | |
WO2019051790A1 (zh) | 单形巨单胞菌(Megamonas funiformis)及其应用 | |
WO2020122396A1 (ko) | 류마티스관절염 개선, 예방 또는 치료를 위한 비피도박테리움 롱검 rapo 균주 및 이를 포함하는 조성물 | |
WO2020076004A1 (ko) | 테트라제노코커스 할로필러스를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물 | |
JP2008054556A (ja) | 免疫賦活作用及び/又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌 | |
CN111979145B (zh) | 人源的粘膜乳杆菌及其用途 | |
WO2020226467A1 (ko) | 면역기능 조절 및 염증성 장질환의 개선효과를 갖는 엔테로코쿠스 락티스 WiKim0107 균주 및 이의 용도 | |
CN111093682B (zh) | 丁酸杆菌(Butyribacter intestini)在预防和/或治疗炎症相关疾病的应用 | |
CN111448306B (zh) | 粪厌氧棒形菌(Anaerofustis stercorihominis)及其应用 | |
US20190240264A1 (en) | Faecalibacterium longum and application thereof | |
WO2022260335A1 (ko) | 갈락토오스를 포함하는 장내 미생물 개체군 개선용 조성물 | |
CN110062806B (zh) | 粪厌氧棒杆菌(Anaerostipes caccae)及其应用 | |
CN110869035B (zh) | 沙氏别样杆菌在制备预防和/或治疗脂质代谢性相关疾病组合物中的应用 | |
WO2019227414A1 (zh) | 一种组合物及其应用 | |
WO2022014893A1 (ko) | 염증성 장질환 예방 또는 치료용 조성물 | |
TWI842979B (zh) | 瑞士乳酸桿菌菌株及含有其之用於預防或治療發炎性疾病的組成物 | |
WO2019227417A1 (zh) | 一种组合物及其应用 | |
WO2022250192A1 (ko) | 항염증 활성이 우수한 김치 유래 신균주 락토바실러스 퍼멘텀 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
CN112867500B (zh) | 人粪厌氧棒形菌在预防和/或治疗代谢性疾病中的用途 | |
WO2021015515A1 (ko) | 페디오코쿠스 이노피나투스를 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21761000 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022545847 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021761000 Country of ref document: EP Effective date: 20220926 |
|
ENP | Entry into the national phase |
Ref document number: 2021229110 Country of ref document: AU Date of ref document: 20210225 Kind code of ref document: A |